cholangitis/fatigue

Tautan disimpan ke clipboard

Pilih jenis pengurutan

Halaman 1 dari 111 hasil

Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Fatigue is the most common complication of primary biliary cholangitis (PBC) and can be debilitating. Numerous interventions have been trialed targeting several proposed mechanisms of PBC-associated fatigue. We sought to summarize and perform a meta-analysis to determine the efficacy

Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634].

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Fatigue is a major clinical problem in many patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). An effective treatment has not been defined. Recently, a large proportion of patients with these diseases was found to have symptoms of depression. Because

Understanding Fatigue in Primary Biliary Cholangitis

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Background: Fatigue affects 50% of primary biliary cholangitis patients and is severe in approximately 20%, significantly affecting quality of life. The pathogenesis of fatigue in primary biliary cholangitis is poorly understood. This

The relation between plasma tyrosine concentration and fatigue in primary biliary cirrhosis and primary sclerosing cholangitis.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND In primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) fatigue is a major clinical problem. Abnormal amino acid (AA) patterns have been implicated in the development of fatigue in several non-hepatological conditions but for PBC and PSC no data are available. This

Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. Half of patients experience debilitating fatigue, which is currently untreatable. Previous studies have shown muscle bioenergetic abnormalities in PBC, including increased muscle acidosis with exercise linked to the

Fatigue in Primary Biliary Cholangitis: no Place for Rituximab.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Patients with Primary Biliary Cholangitis (PBC) have experienced major therapeutic progress during the last four decades. An effective first line therapy, ursodeoxycholic acid (UDCA), is available from which all patients, responders as well as 'incomplete' responders, appear to benefit according to

NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

NI-0801 is a fully human monoclonal antibody against chemokine (C-X-C motif) ligand 10 (CXCL10), which is involved in the recruitment of inflammatory T cells into the liver. The safety and efficacy of NI-0801 was assessed in patients with primary biliary cholangitis. In this open-label phase 2a

Clinical Review Report: Obeticholic Acid (Ocaliva): (Intercept Pharmaceuticals Canada, Inc.): Indication: For the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Primary biliary cholangitis (PBC) occurs as a result of immune-mediated damage to bile ducts, with an associated inflammatory response leading to progressive fibrosis and loss of patency. This loss of patency leads, in turn, to hepatic accumulation of bile acids, resulting in liver damage with

Current and promising therapy for primary biliary cholangitis.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Primary biliary cholangitis is a chronic, cholestatic liver disease that may progress to cirrhosis with complications of end-stage liver disease. Approved treatment options include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) but novel therapies are being

[Primary biliary cholangitis-established and novel therapies].

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Patients with primary biliary cholangitis (PBC, formerly primary biliary cirrhosis) and insufficient treatment response or risk factors exhibit a remarkably increased risk for disease progression and associated complications. Furthermore, extrahepatic manifestations may considerably reduce quality

What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by chronic cholestasis. Treatment with the accepted primary therapy ursodeoxycholic acid (UDCA) has been shown to be associated with delayed disease progression probably through reduced impact of cholestatic injury on

Primary sclerosing cholangitis.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Primary sclerosing cholangitis (PSC) is a chronic cholestatic syndrome of unknown etiology frequently associated with inflammatory bowel disease and characterized by diffuse inflammation and fibrosis of the intra and/or extrahepatic bile ducts. Recent studies seem to favor autoimmunity in the

Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Data concerning the usefulness and type of drugs employed to treat patients with primary sclerosing cholangitis are controversial. Ursodeoxycholic acid has been shown to be a useful agent, however the drug dosage and its effect on the clinical course are still under debate. OBJECTIVE To

Emerging drugs for the treatment of Primary Biliary Cholangitis.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

BACKGROUND Primary biliary cholangitis (PBC) is an autoimmune chronic disease of the liver that can progress to cirrhosis and hepatocellular carcinoma. It affects approximately 1 in 4,000 with a 10:1 female to male ratio. The diagnosis of PBC can be made based on serum antimitochondrial antibodies

Primary sclerosing cholangitis.

Hanya pengguna terdaftar yang dapat menerjemahkan artikel

Masuk daftar

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the bile ducts, resulting in end-stage liver disease and reduced life expectancy. PSC primarily affects young and middle-aged men, often in association with underlying

Sebelumnya
1
2
3
4
5
6
7
8
Lanjut

Bergabunglah dengan
halaman facebook kami

Herbal & Natural Medicine

Database tanaman obat terlengkap yang didukung oleh sains

Bekerja dalam 55 bahasa
Pengobatan herbal didukung oleh sains
Pengenalan herbal melalui gambar
Peta GPS interaktif - beri tag herba di lokasi (segera hadir)
Baca publikasi ilmiah yang terkait dengan pencarian Anda
Cari tanaman obat berdasarkan efeknya
Atur minat Anda dan ikuti perkembangan berita, uji klinis, dan paten

Ketikkan gejala atau penyakit dan baca tentang jamu yang mungkin membantu, ketik jamu dan lihat penyakit dan gejala yang digunakan untuk melawannya.
* Semua informasi didasarkan pada penelitian ilmiah yang dipublikasikan